Immuno-oncology start-up Arcus emerges.

The article focuses on the growth potential of Arcus Biosciences established by Terry Rosen and Juan Jaen. Topics covered include the amount of venture capital funding raised by the company, the development of compounds in the field of immuno-oncology and the creation of compounds intended to disrupt enzymatic conversion of adenosinetriphosphate (ATP) into adenosine.